The concentration of CYFRA 21-1, NSE and CEA in cerebro-spinal fluid can be useful indicators for diagnosis of meningeal carcinomatosis of lung cancer

Wang, Peng; Piao, Yingzhe; Zhang, Xiaohui; Li, Wenliang; Hao, Xishan

doi:10.3233/cbm-130338

Cited by 49 publications

(36 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The clinical use of NSE has significantly improved the sensitivity and specificity of lung cancer diagnosis and may be useful for pathological typing (21). The combination of CEA and NSE may be an effective clinical confirmation and exclusive diagnostic indictor of meningeal carcinomatosis in lung cancer (38). In the present study, it was observed that BsAbCENS targeted CEA and NSE on lung cancer cells.…”

Section: Discussionsupporting

confidence: 51%

Contrast‑enhanced magnetic resonance imaging with a novel nano‑size contrast agent for the clinical diagnosis of patients with lung cancer

Gao

Liu

et al. 2018

Exp Ther Med

View full text Add to dashboard Cite

Abstract. Recent studies have indicated that magnetic resonance imaging (MRI) efficiently diagnoses lung cancer. However, the efficacy of MRI in diagnosing lung cancer requires improving for patients in the early stage of the disease. In the present study, a novel nano-sized contrast agent of chistosan/Fe 3 O 4 -enclosed bispecific antibodies (BsAbCENS) was introduced, which targeted carcino-embryonic antigen (CEA) and neuron-specific enolase (NSE) in lung cancer cells. The diagnostic efficacy of contrast-enhanced MRI with BsAbCENS (CEMRI-BsAbCENS) was investigated in a total of 182 patients with suspected lung cancer who had high serum levels of CEA and NSE. BsAbCENS was administered by pulmonary inhalation prior to the MRI scan. The results revealed that CEA and NSE were overexpressed in human lung cancer cell lines. BsAbCENS bound with CEA and NSE on the surface of human lung cancer cells and produced a higher signal intensity than MRI alone for the diagnosis of patients with lung cancer. The diagnostic data revealed that CEMRI-BsAbCENS diagnosed 124/182 lung cancer cases, whereas CEMRI only diagnosed 98/182, which was significantly less (P<0.01). In addition, the survival rate of patients with lung cancer diagnosed by CEMRI-BsAbCENS was significantly higher than the mean 5-year survival rate (P<0.01). Furthermore, the pharmacodynamics demonstrated that BsAbCENS was metabolized within 24 h. The results of the present study indicate that the efficacy and accuracy of lung cancer diagnosis are improved by CEMRI-BsAbCENS. In conclusion, these results provide a potential novel protocol for the diagnosis of tumors in patients with suspected early stage lung cancer.

show abstract

Section: Discussionsupporting

confidence: 51%

Contrast‑enhanced magnetic resonance imaging with a novel nano‑size contrast agent for the clinical diagnosis of patients with lung cancer

Gao

Liu

et al. 2018

Exp Ther Med

View full text Add to dashboard Cite

show abstract

“…Up to now, a series of biomarkers for discerning lung cancer and monitoring progress have been detected in serum, such as CEA, CYFRA21-1, NSE, and so on (19,20). Serum biomarkers predicting patient prognosis or response to therapy may make progress in the potential of personalized medicine in cancer treatment.…”

Section: Discussionmentioning

confidence: 99%

Increased stathmin in serum as a potential tumor marker for lung adenocarcinoma

Biaoxue

Liu

Tian

et al. 2017

Japanese Journal of Clinical Oncology

View full text Add to dashboard Cite

Background: Stathmin has been found to be involved in malignant tumors; the aim of this study was to investigate the relationship between serum stathmin and clinico-pathological features of lung cancer. Methods: In three lung cancer cell lines, stathmin expression and its secretion level in the supernatant were examined by Western blot and enzyme-linked immunosorbent assay (ELISA). Expression of stathmin was examined by immunohistochemistry in 48 lung cancer tissues, and serum stathmin expression level was examined by ELISA in 96 patients with lung cancer and 82 normal individuals. Sensitivity and specificity of serum stathmin were determined by receiver operator characteristic curve (ROC). Results: In the three cell lines and their supernatant, stathmin levels were higher than those in 16 HBE cell line. Lung cancer tissues expressed higher level stathmin more frequently than normal lung tissue (P < 0.05). Serum stathmin level was significantly higher in the patients with lung cancer than in normal individuals (P < 0.001). Increased stathmin level in cancer tissue and serum were significantly associated with adenocarcinoma histology, lymph node metastasis and advanced stage. The threshold level of serum stathmin for distinguishing lung cancer from normal individuals was 1.86 ng/ml. The sensitivity and specificity were 93.7% and 91.5%, respectively. Conclusions: Measurement of serum stathmin level could be a potential biomarker for lung cancer, especically those of adenocarcinoma, with lymph node metastasis and at advanced clinical stages.

show abstract

“…Considering that tumor biomarkers are produced directly by the tumor or by non-tumor cells as a response to the presence of tumor cells, the elevation of tumor biomarkers can be detected earlier than radiographic abnormalities5. Investigating specific molecular markers in airways might serve as an important adjunct to routine examination for lung cancer diagnosis.…”

mentioning

confidence: 99%

TGF-β1, IL-6 and TNF-α in Bronchoalveolar Lavage Fluid: Useful Markers for Lung Cancer?

Chen

Sun

et al. 2014

Sci Rep

View full text Add to dashboard Cite

Changes of cytokines in bronchoalveolar lavage fluid (BALF) reflect immunologic reactions of the lung in pulmonary malignancies. Detection of biomarkers in BALF might serve as an important method for differential diagnosis of lung cancer. A total of 78 patients admitted into hospital with suspected lung cancer were included in our study. BALF samples were obtained from all patients, and were analyzed for TGF-β1, IL-6, and TNF-α using commercially available sandwich ELISA kits. The levels of TGF-β1 in BALF were significantly higher in patients with lung cancer compared with patients with benign diseases (P = 0.003). However, no significant difference of IL-6 (P = 0.61) or TNF-α (P = 0.72) in BALF was observed between malignant and nonmalignant groups. With a cut-off value of 10.85 pg/ml, TGF-β1 showed a sensitivity of 62.2%, and a specificity of 60.6%, in predicting the malignant nature of pulmonary disease. Our data suggest that TGF-β1 in BALF might be a valuable biomarker for lung cancer. However, measurement of IL-6 or TNF-α in BALF has poor diagnostic value in lung cancer.

show abstract

The concentration of CYFRA 21-1, NSE and CEA in cerebro-spinal fluid can be useful indicators for diagnosis of meningeal carcinomatosis of lung cancer

Cited by 49 publications

References 29 publications

Contrast‑enhanced magnetic resonance imaging with a novel nano‑size contrast agent for the clinical diagnosis of patients with lung cancer

Contrast‑enhanced magnetic resonance imaging with a novel nano‑size contrast agent for the clinical diagnosis of patients with lung cancer

Increased stathmin in serum as a potential tumor marker for lung adenocarcinoma

TGF-β1, IL-6 and TNF-α in Bronchoalveolar Lavage Fluid: Useful Markers for Lung Cancer?

Contact Info

Product

Resources

About